In addition, numerous FXR modulators have been discovered and their efficacy has been evaluated for the treatment of FXR-mediated liver diseases, such as PBC, NASH, biliary atresia, and APAP-induced liver failure. The gene discussed is NR1H4; the disease is biliary atresia.